Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Immediate Postpartum LARC Implementation Programs

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03118726
Recruitment Status : Completed
First Posted : April 18, 2017
Last Update Posted : August 28, 2019
Sponsor:
Information provided by (Responsible Party):
Lisa Hofler, University of New Mexico

Brief Summary:
This study will engage hospitals working with the New Mexico Perinatal Collaborative (NMPC) on implementing immediate postpartum long-acting reversible contraception programs. All hospitals in New Mexico interested in implementing immediate postpartum LARC programs will be eligible to participate in the NPMC program evaluation. The study will evaluate the components of this implementation program at several New Mexico hospitals using a stepped wedge design,with components being introduced to each hospital one at a time

Condition or disease
Post Partum Contraception

Layout table for study information
Study Type : Observational
Actual Enrollment : 21 participants
Observational Model: Cohort
Time Perspective: Other
Official Title: Evaluation of Immediate Postpartum LARC Implementation Programs
Actual Study Start Date : April 13, 2017
Actual Primary Completion Date : May 31, 2018
Actual Study Completion Date : May 31, 2019

Resource links provided by the National Library of Medicine


Group/Cohort
NM Perinatal Collaborative
Hospitals working with the New Mexico Perinatal Collaborative (NMPC) on implementing immediate postpartum long-acting reversible contraception programs.



Primary Outcome Measures :
  1. Baseline immediate postpartum LARC Implementation [ Time Frame: April 2017-December 2018 ]
    To determine baseline immediate postpartum LARC implementation in various rural New Mexico hospitals.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Hospitals working with the New Mexico Perinatal Collaborative (NMPC) on implementing immediate postpartum long-acting reversible contraception programs. All hospitals in New Mexico interested in implementing immediate postpartum LARC programs will be eligible to participate in the NPMC program evaluation. The study will evaluate the components of this implementation program at several New Mexico hospitals using a stepped wedge design, with components being introduced to each hospital one at a time.
Criteria

Inclusion Criteria:

  • Hospital staff: Important individuals at New Mexico hospitals planning to implement immediate postpartum LARC programs, with an emphasis on diversity of administrative perspectives.
  • If more than 4 potential participants are identified at one institution, additional participants may be included if their participation in the study is likely to contribute additional information (e.g. job title or background is different from other study participants)

Exclusion Criteria:

- Inability to speak and read English proficiently


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03118726


Locations
Layout table for location information
United States, New Mexico
University of New Mexico
Albuquerque, New Mexico, United States, 87131
Sponsors and Collaborators
University of New Mexico
Investigators
Layout table for investigator information
Principal Investigator: Lisa Hofler, MD, MBA, MPH University of New Mexico
Layout table for additonal information
Responsible Party: Lisa Hofler, Assistant Professor, University of New Mexico
ClinicalTrials.gov Identifier: NCT03118726    
Other Study ID Numbers: 17-051
First Posted: April 18, 2017    Key Record Dates
Last Update Posted: August 28, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Lisa Hofler, University of New Mexico:
LARC
New Mexico
Contraception